312 related articles for article (PubMed ID: 12113120)
1. Temozolomide: a novel oral alkylating agent.
Danson SJ; Middleton MR
Expert Rev Anticancer Ther; 2001 Jun; 1(1):13-9. PubMed ID: 12113120
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide and treatment of malignant glioma.
Friedman HS; Kerby T; Calvert H
Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Agarwala SS; Kirkwood JM
Oncologist; 2000; 5(2):144-51. PubMed ID: 10794805
[TBL] [Abstract][Full Text] [Related]
4. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
5. New approaches for temozolomide therapy: use in newly diagnosed glioma.
Stupp R; Newlands E
Semin Oncol; 2001 Aug; 28(4 Suppl 13):19-23. PubMed ID: 11550135
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide for Treating Malignant Melanoma.
Li RH; Hou XY; Yang CS; Liu WL; Tang JQ; Liu YQ; Jiang G
J Coll Physicians Surg Pak; 2015 Sep; 25(9):680-8. PubMed ID: 26374366
[TBL] [Abstract][Full Text] [Related]
7. [Prescription guidebook for temozolomide usage in brain tumors].
Tilleul P; Brignone M; Hassani Y; Taillandier L; Taillibert S; Cartalat-Carel S; Borget I; Chinot O
Bull Cancer; 2009 May; 96(5):579-89. PubMed ID: 19467988
[TBL] [Abstract][Full Text] [Related]
8. Future directions for temozolomide therapy.
Yung WK
Semin Oncol; 2001 Aug; 28(4 Suppl 13):43-6. PubMed ID: 11550138
[TBL] [Abstract][Full Text] [Related]
9. Optimal role of temozolomide in the treatment of malignant gliomas.
Stupp R; van den Bent MJ; Hegi ME
Curr Neurol Neurosci Rep; 2005 May; 5(3):198-206. PubMed ID: 15865885
[TBL] [Abstract][Full Text] [Related]
10. [Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Matsko MV
Vopr Onkol; 2012; 58(3):425-8. PubMed ID: 22888663
[No Abstract] [Full Text] [Related]
11. Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Friedman HS
Semin Oncol; 2000 Jun; 27(3 Suppl 6):35-40. PubMed ID: 10866348
[TBL] [Abstract][Full Text] [Related]
12. Current and future developments in the use of temozolomide for the treatment of brain tumours.
Stupp R; Gander M; Leyvraz S; Newlands E
Lancet Oncol; 2001 Sep; 2(9):552-60. PubMed ID: 11905710
[TBL] [Abstract][Full Text] [Related]
13. Oral temozolomide approved for refractory brain tumor.
Miller JL
Am J Health Syst Pharm; 1999 Oct; 56(19):1910. PubMed ID: 10554903
[No Abstract] [Full Text] [Related]
14. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide in malignant gliomas.
Yung WK
Semin Oncol; 2000 Jun; 27(3 Suppl 6):27-34. PubMed ID: 10866347
[TBL] [Abstract][Full Text] [Related]
18. [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Frick S; Lischner S; Rosien F; Haacke TC; Schäfer F; Christophers E; Hauschild A
Hautarzt; 2002 Oct; 53(10):659-65. PubMed ID: 12297947
[TBL] [Abstract][Full Text] [Related]
19. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Hillner BE; Agarwala S; Middleton MR
J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Teimouri F; Nikfar S; Abdollahi M
Melanoma Res; 2013 Oct; 23(5):381-9. PubMed ID: 23880781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
